Biotechs Combine to Target Type 1 Diabetes Treatment

Important Disclosures:

1. Sernova Biotherapeutics Inc. has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
2. As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Sernova Biotherapeutics Inc.
3. Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
4. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

Sernova Biotherapeutics Inc. (SVA:TSX; SEOVF:OTCQB; PSH0:XETRA) and private company Seraxis Holdings Inc. have entered into a definitive agreement to merge their businesses and technologies, creating BetaNova Biotherapeutics, a U.S.-based clinical-stage biotechnology company focused on developing a new approach to islet cell replacement for type 1 diabetes (T1D), according to a September 8 release.

BetaNova will be headquartered in Germantown, Maryland, with integrated research laboratories and cGMP (current Good Manufacturing Practice) capabilities, the release said. Shareholders of Sernova and Seraxis are expected to each hold approximately 50% of the combined company.

The transaction is supported by commitments for a US$10 million non-brokered convertible note financing from existing insider shareholders of both companies. The financing will remain open to other qualified investors through September 30. Once the merger closes, the notes will automatically convert into non-voting BetaNova common shares, which holders may convert into voting shares subject to beneficial ownership restrictions.

The financing is expected to fund several key development milestones, including cGMP production of SR-02 stem cell-derived pancreatic islet cells; initiation of a Phase 1/2 T1D clinical trial in the first quarter of 2027, with initial data expected by mid-2027; preparation for a Nasdaq listing during the first quarter of 2027; and continued development of an investigational new drug application for SR-03 in the second half of 2027.

BetaNova's lead candidate, SR-02, is an allogeneic stem cell-derived pancreatic islet therapy designed for use with next-generation, lower-toxicity immunosuppressants, with the longer-term objective of establishing immune tolerance and eliminating chronic immunosuppression, according to the release. Its follow-on candidate, SR-03, incorporates gene edits intended to enable immune evasion and potentially remove the need for immunosuppression.

The combined pipeline will also draw on Sernova's clinical work with its Cell Pouch Bio-hybrid Organ, an implantable and retrievable device designed to support the survival, engraftment, and function of pancreatic islet cells. Sernova has completed patient treatment and follow-up in its Phase 1/2 study involving donor-derived pancreatic islets in people with T1D, with all primary and secondary endpoints achieved and more than 30 years of cumulative patient safety data supporting the platform.

"This merger is deeply personal to me — I've lived with and suffered from type 1 diabetes most of my life, and it drives my passion to overcome it," said Jonathan Rigby, president and chief executive officer of Sernova and proposed CEO of BetaNova. "People with T1D struggle to manage the life-altering loss of insulin production, often resulting in serious co-morbidities. Combining Sernova's Cell Pouch Bio-hybrid Organ with Seraxis' stem cell-derived pancreatic islet cells lets us approach the problem differently, bringing us closer to a functional cure. This is very exciting to me and our entire team."

Will Rust, PhD, president and CEO of Seraxis and proposed president and chief scientific officer of BetaNova, said the combined platform addresses several hurdles that have limited islet cell replacement, including scalable manufacturing, successful engraftment, and protection of transplanted cells from immune attack.

BetaNova will bring together Seraxis' stem cell-derived islets, manufacturing capabilities, and immune-evasion strategy with Sernova's Cell Pouch Bio-hybrid Organ, an implantable and retrievable device designed to support islet cell survival, engraftment, and function.

Noble Capital Markets Inc. served as exclusive financial adviser to the merger, the release said. The companies will hold a webinar on September 11 at 10 a.m. ET to discuss the definitive agreement.

Sernova Wins Orphan Drug Designation for Cell Pouch Approach

In June, Sernova announced it had received U.S. Food and Drug Administration orphan drug designation for autologous islet transplantation (AIT) to prevent diabetes following total pancreatectomy. The designation supports the company's development of its Cell Pouch Bio-hybrid Organ as a potential treatment for type 3c diabetes (T3cD), a condition that can develop after pancreatic removal and shares characteristics and complications with type 1 diabetes.

Sernova's Cell Pouch is designed to provide an environment where transplanted therapeutic cells can establish a blood supply and continue functioning. The planned approach would use insulin-producing islet cells taken from a patient's own removed pancreas and implanted into the vascularized Cell Pouch, with the goal of maintaining insulin production after surgery while avoiding immunosuppressing drugs.

Dr. Melena Bellin, co-director of the Total Pancreatectomy and Islet Autotransplant Program at the University of Minnesota and a member of Sernova's Clinical Advisory Board, said the therapy could address the immediate loss of pancreatic endocrine function that follows total pancreatectomy.

"Patients who require total pancreatectomy face a life-changing outcome: the immediate loss of pancreatic endocrine function and the risk of complex, insulin-dependent diabetes," she said. "Autologous islet transplantation in Sernova's Cell Pouch has the potential to preserve a patient's own insulin-producing cells following pancreatic surgery, without the use of immune-suppressing therapies."

The FDA's orphan drug designation applies to therapies targeting rare diseases or conditions affecting fewer than 200,000 people in the United States and can provide several development benefits. For Sernova, these may include seven years of U.S. market exclusivity following approval, potential tax credits for eligible clinical testing, and possible exemptions from certain FDA user fees.

"Receiving Orphan Drug Designation from the FDA is an important milestone for Sernova," Rigby said at the time. "Our primary focus remains on advancing a functional cure for type 1 diabetes. At the same time, this designation provides Sernova a potential exclusive lead position in preventing type 3c diabetes. T3cD is a natural extension of our primary focus on T1D, and we are planning to advance."

Wainwright Keeps Buy, Trims Target on Merger Math

In an updated September 8 research note, H.C. Wainwright & Co. reiterated its Buy rating on Sernova Corp. while lowering its price target to CA$1 from CA$6, after the company agreed to merge with privately held Seraxis to create the new company.

The firm attributed the lower target mainly to updated fully diluted share counts and to swapping its Cell Pouch projections for the merged company's earlier-stage Seraxis programs, rather than a dimmer view of the science. Sernova and Seraxis shareholders would each own about 50% of BetaNova, insiders of both have committed to a US$10 million convertible note financing, and the deal is expected to close in November 2026. The combined company is expected to remain listed on the TSX and intends to seek a Nasdaq listing in the first quarter of 2027, subject to applicable listing requirements and approvals.

The report framed the combination as strengthening an integrated diabetes platform, pairing Sernova's Cell Pouch implant with Seraxis' stem cell-derived pancreatic islets and in-house cGMP manufacturing.

"We view the strategic rationale for the merger as a good move, as the combination brings together Sernova's Cell Pouch with Seraxis' stem cell-derived pancreatic islets, in-house cGMP manufacturing capabilities, and approaches aimed at reducing or eliminating chronic immunosuppression," the report said.

The near-term catalyst is BetaNova's lead candidate, SR-02, an allogeneic stem cell-derived islet therapy with an FDA-cleared IND, with initial Phase 1/2 dosing expected in the first quarter of 2027 and data by mid-2027. The firm flagged one key unknown — whether Seraxis' cells will perform inside the Cell Pouch.

"The clinical performance of Seraxis' cells in combination with the Cell Pouch has yet to be reported," the report said, while describing both SR-02 and the follow-on SR-03 as carrying blockbuster potential for projected 2032 and 2033 launches.

The Catalyst: Diabetes Drug Market Heading Toward US$283 Billion

More than 40 million Americans, about 12% of the population, are living with diabetes, according to the Centers for Disease Control and Prevention. Of the roughly 40.1 million people with the disease, 29.1 million are diagnosed, and about 11.0 million, or 27.6% of adults with diabetes, remain undiagnosed. Prevalence rises sharply with age, reaching 28.8% among Americans 65 and older, and another 115.2 million U.S. adults are living with prediabetes.

By type, the CDC data show Type 2 diabetes accounts for 90% to 95% of all diagnosed adult cases, while Type 1 diabetes affects about 2.1 million people, including 314,000 children and adolescents.

The global diabetes drug market is expected to expand significantly, increasing from US$101.48 billion in 2025 to US$116.11 billion in 2026 and reaching US$283.36 billion by 2034, according to Fortune Business Insights. The market is projected to advance at an 11.80% CAGR during the forecast period, with North America accounting for 49.95% of global revenue in 2025. Novo Nordisk (NVO:NYSE), Eli Lilly and Co. (LLY:NYSE), and Sanofi SA (SNY:NYSE) are among the major companies driving the sector.

Diabetes remains a growing worldwide health challenge. The International Diabetes Federation estimates that 537 million adults were living with the disease in 2021, with that total expected to reach 643 million by 2030 and 783 million by 2045. Beyond its health effects, diabetes creates a substantial economic burden through related complications, reduced quality of life, and shortened life expectancy.

Market growth is being supported by the increasing incidence of diabetes, population aging, and improvements in drug delivery. Treatments for type 1 and type 2 diabetes include insulin, GLP-1 receptor agonists, and SGLT2 inhibitors, which can be delivered orally, intravenously, or through subcutaneous administration to help control blood glucose levels.

Ownership and Share Structure¹

About 10.74% of Sernova before the merger is held by insiders and management, and about 0.04% by institutions. The rest is retail.

Top shareholders include Director Steven Sangha with 10.51%, Chief Financial Officer James Parsons with 0.16%, CEO Rigby with 0.06%, and CATAM Asset Management AG with 0.04%.

Sernova has 377.64 million outstanding shares. Its market cap is approximately CA$56.65 million. Its 52-week range is CA$0.10−CA$0.20 per share.

Common Investor Questions

What did Sernova announce? Sernova Biotherapeutics Inc. signed a definitive agreement to merge with privately held Seraxis Holdings Inc. to create BetaNova Biotherapeutics, a U.S.-based clinical-stage company developing a new approach to islet cell replacement for type 1 diabetes, according to a September 8 release.

What is BetaNova, and who will own it? BetaNova will be headquartered in Germantown, Maryland, with integrated research labs and cGMP manufacturing. Sernova and Seraxis shareholders are each expected to own about 50% of the combined company, which is expected to remain listed on the TSX and to pursue a Nasdaq listing in the first quarter of 2027.

How is the merger being financed? The transaction is backed by commitments for a US$10 million non-brokered convertible note financing from insiders of both companies, open to other qualified investors through September 30. On closing, the notes automatically convert into non-voting BetaNova shares, convertible to voting shares subject to ownership limits. The financing is meant to fund SR-02 manufacturing, the Phase 1/2 trial, Nasdaq listing preparation, and SR-03 development.

What are the lead programs? BetaNova's lead candidate, SR-02, is an allogeneic stem cell-derived pancreatic islet therapy meant to be used with lower-toxicity immunosuppressants, with the longer-term goal of eliminating chronic immunosuppression. Follow-on candidate SR-03 adds gene edits intended to enable immune evasion. Both would draw on Sernova's Cell Pouch, an implantable, retrievable device that supports transplanted islet cells; Sernova has completed its Phase 1/2 Cell Pouch study in T1D with all primary and secondary endpoints met and more than 30 years of cumulative patient safety data.

What was the June orphan drug designation? In June, Sernova received FDA orphan drug designation for autologous islet transplantation to prevent diabetes following total pancreatectomy, supporting the Cell Pouch as a potential treatment for type 3c diabetes. The designation can bring up to seven years of U.S. market exclusivity after approval, tax credits for eligible testing, and possible user-fee exemptions.

What do analysts say? H.C. Wainwright & Co. reiterated a Buy while lowering its target to CA$1 from CA$6, attributing the cut mainly to updated fully diluted share counts and to substituting the earlier-stage Seraxis programs for its Cell Pouch projections, not a dimmer view of the science. It called the strategic rationale "a good move" but flagged that the performance of Seraxis' cells inside the Cell Pouch has not yet been reported.

What are the key milestones ahead? The merger is expected to close in November 2026, subject to shareholder approval. Initial Phase 1/2 dosing of SR-02 is expected in the first quarter of 2027, with data by mid-2027; an SR-03 IND is targeted for the second half of 2027; and a Nasdaq listing is planned for the first quarter of 2027.